Bioventus Class A BVS 深 沪
等待开盘 09-03 09:30:00 美东时间
7.235
-0.165
-2.23%
华盛通- 最 高7.435
- 今 开7.31
- 成交量 11.72万股
- 最 低 7.1829
- 昨 收 7.40
- 总市值 4.84亿
- 52周最高 14.38
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.81
- 委 比 43.31%
- 总股本 6689.23万
- 历史最高 19.941
- 量 比 0.22
- 振 幅 3.41%
- 历史最低 0.7999
- 每 手 1
- 风险率 2.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bravura Solutions Announces 2025 AGM Date and Director Elections
The latest update is out from Bravura Solutions Limited ( ($AU:BVS) ). Bravura ...
08-20 13:37
Bravura Solutions Announces Chairman’s Retirement
Bravura Solutions Limited ( ($AU:BVS) ) has shared an announcement. Bravura Sol...
08-13 08:29
22.5亿美元医疗黑科技炸场：美敦力、强生、GE医疗等巨头疯狂入局
（来源：医趋势） 8月7日，美国医疗器械企业HistoSonics宣布，一个由私募和公募投资者组成的联盟已完成对其多数股权的收购，此次收购由公司管理层主导。...
08-11 12:05
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference
Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced that CEO Rob Claypoole will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on August 12, 2025, at 2:00 p.m. ET. A live webcast with a Q&A session will be available on the company’s website, www.bioventus.com, followed by a replay.
08-07 20:15
Bioventus Q2 Adj. EPS $0.21, Inline, Sales $147.660M Beat $146.284M Estimate
Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.21 per share which met the analyst consensus estimate. This is a 31.25 percent increase over earnings of $0.16 per share from the same period last year. The
08-06 19:03
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
Bioventus Inc. has entered into a $400 million Senior Secured Credit Agreement, including a $300 million term loan and a $100 million revolving credit facility, maturing on July 31, 2030. The agreement enhances liquidity, reduces the applicable interest margin by 75 basis points, and lowers annual term loan amortization from 10% to 5%. Proceeds were used to repay $333 million under the previous 2019 Credit Agreement, with $30 million from the new...
08-04 12:00
The FDA Grants 510(k) Clearances For Bioventus' Talismann And Stimtrial, Expanding The Company's Portfolio Of Peripheral Nerve Stimulation Solutions For Chronic Pain Management
These two clearances mark an important step forward for Bioventus and represent a substantial growth opportunity as the Company looks to expand in the PNS market, which is currently estimated to be growing above 20
07-30 19:36
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
Bioventus Inc. announced FDA 510(k) clearances for TalisMann™ and StimTrial™, expanding its PNS solutions for chronic pain management. These approvals position the company for growth in a market projected to exceed $500 million by 2029. TalisMann™ features advanced technology for deeper nerve stimulation, while StimTrial™ allows for patient response evaluation. Limited commercial release will begin in Q3 2025, with broader rollout in early 2026. ...
07-30 11:30
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
Bioventus Inc. (Nasdaq: BVS) announced it will report second-quarter fiscal 2025 financial results on August 6, 2025, before the market opens. Management will host a conference call at 8:30 a.m. ET the same day to discuss the results. Participants can dial 1-800-715-9871 (conference ID 1859022) or access the live webcast at https://ir.bioventus.com/. The webcast will be archived until August 5, 2026. Bioventus delivers clinically proven, cost-eff...
07-29 20:15
